Home › Therapure Innovations Receives FDA Approval To Proceed With A Phase 1 Clinical Trial Of The Targeted Liver Cancer Therapeutic TBI 302
 

Keywords :   


Therapure Innovations Receives FDA Approval To Proceed With A Phase 1 Clinical Trial Of The Targeted Liver Cancer Therapeutic TBI 302

2015-04-01 08:23:10| drugdiscoveryonline Home Page

Therapure Innovations, a division of Therapure Biopharma Inc., recently announces that the U.S. Food and Drug Administration (FDA) has given the company approval to proceed with a Phase 1 clinical trial of TBI 302, a targeted therapeutic for the treatment of liver cancer

Tags: trial phase approval cancer

Category:Biotechnology and Pharmaceuticals

Latest from this category

All news
»
03.05Mary Kay Inc. Expands into Denmark
03.05Hotel Collection Teams with Lucasfilm to Create Scented Universe for National Star Wars Day
03.05This Week in Waste: Top Stories April 29 May 2, 2024
03.05FENC Uncaps Major Success with Global Sustainable Expansion in Recycled Polyester
03.05Klamath Falls, OR. Receives Funds to Improve Water Recycling Quality, Supply
03.05Walmart to use Generative AI to Help Reduce Food Waste in Stores
03.05FCC Environmental Services Expands Midwest Presence, Compressed Natural Gas Operations
03.05Farm Progress America, May 3, 2024
More »